Table 2 Factors associated with viral suppression among clients on protease inhibitor-based ART who underwent Intensive Adherence Counseling at an urban public HIV care center in Uganda
Characteristic | Not suppressed (n = 91) | Suppressed (n = 95) | Crude Odds Ratio | P-value | Adjusted Odds Ratio (95% CI) | P-value |
|---|---|---|---|---|---|---|
Age (median, IQR) | 35(25–43) | 35(11–44) | 1 | 0.077 | 1 (0.97–1.01) | 0.283 |
Sex | Â | Â | Â | Â | Â | Â |
Male (37.8%) | 32(35.2) | 37 (39.0) | 1 | Â | 1 | Â |
Female (62.2%) | 59 (64.8) | 58 (61.1) | 0.9 | 0.594 | 0.8 (0.45–1.54) | 0.552 |
Current ART regimen | Â | Â | Â | Â | Â | Â |
Atazanavir/Ritonavir- based (61.6%) | 61 (67.0) | 51 (57.3) | 1 | Â | 1 | Â |
Lopinavir/Ritonavir- based (38.4%) | 30 (33.0) | 44 (46.3) | 1.8 | 0.064 | 1.4 (0.70–2.92) | 0.321 |
Years on PI-based ART (median, IQR) | 5 (5–6) | 6 (4–6) | 1 | 0.858 | 1.1 (0.83–1.40) | 0.583 |
Number of IAC sessions received (median, IQR) | 3 (3–4) | 3 (3–4) | 0.8 | 0.325 | 0.7 (0.45–1.01) | 0.054 |
Duration on IAC in months | 3 (2–4) | 3 (2–4) | 1.2 | 0.053 | 1.3 (1.04–1.55) | 0.018 |